Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Research & Development · Q4 FY2025 · quarter ended Dec 2025

Research & development grows 16.8% year over year

Q4 FY2025 research & development of CN¥587.52M rose 16.8% year over year. Over 3 fiscal years it compounded at +13.4% a year.

Context

  • Research & development amounted to 194.0% of revenue in FY2025, up 97.4 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
CN¥587.52M— QoQ
Last fiscal yearDec 2025
CN¥1.08B+14.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.8%——
1 year+14.4%——
3-year CAGR+13.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

CNY · from the income statement

Latest · FY2025
1.08B CNY
Year-over-year change
+14.4%
4-year CAGR
+9.0%

Research & Development vs competitors

How AAPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.4% is the 4th highest of 10, against a peer median of +10.2%.
  • Research & development amounts to 194.0% of revenue for AAPG, versus a peer median of 150.7%.
AAPG Competitors
Research & Development for AAPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$10.68B USD+22061.7%+5.1%—
AAPGAscentage Pharma Group InternationalFY2025CN¥1.08B CNY+14.4%+13.4%194.0%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$339.54M USD+5.2%+52.0%150.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M USD+10.2%+18.6%47.3%
ZLABZai Lab LimitedLTM Jun 2026$236.92M USD+3.2%-8.3%52.7%
TNGXTango Therapeutics, Inc.LTM Sep 2026$152.48M USD+14.3%+7.7%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$129.68M USD+5.2%+71.4%—
NUVBNuvation Bio Inc.LTM Jun 2026$128.85M USD+18.2%+9.4%75.8%
VSTMVerastem, Inc.LTM Mar 2026$123.67M USD+33.3%+31.4%249.4%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M USD-11.6%-4.0%291.9%
ANLAdlai Nortye Ltd.LTM Jun 2024$56.93M USD—-15.5%877.1%
Peer median (excluding AAPG) —+10.2%+8.6%150.7%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.91M209.71M221.98M980.65M558.48M
Cost of Revenue3.33M22M30.54M29.09M131.73M
Gross Profit24.58M187.71M191.44M951.57M426.75M
Gross Margin88.1%89.5%86.2%97.0%76.4%
Research & Development766.49M743.1M706.97M947.25M1.08B
Selling, General & Admin191.26M328.02M376.46M383.12M522.67M
Operating Expenses957.75M1.04B1.06B1.32B1.61B
Depreciation & Amortization17.18M47.42M93.2M93.17M84.12M
EBITDA(798.34M)(786.97M)(743.61M)(237.63M)(1.1B)
EBITDA Margin-2860.4%-375.3%-335.0%-24.2%-196.1%
Operating Income(869.84M)(849.81M)(872.64M)(369.73M)(1.18B)
Operating Margin-3116.6%-405.2%-393.1%-37.7%-211.1%
Interest Income7.11M9.73M32.41M37.84M79.89M
Interest Expense16.73M52.79M96.06M64.46M52.6M
Other Income / Expenses37.59M(37.36M)(60.23M)(25.53M)(23.21M)
Income Before Tax(832.25M)(887.17M)(932.86M)(395.26M)(1.2B)
Pre-Tax Margin-2981.9%-423.0%-420.2%-40.3%-215.3%
Income Tax Expense(49.83M)(4.25M)(7.15M)10.43M6.75M
Net Income(782.42M)(882.92M)(925.64M)(405.43M)(1.21B)
Net Margin-2803.4%-421.0%-417.0%-41.3%-216.5%
EPS (Basic)(49.12)(53.60)(52.48)(5.36)(13.56)
EPS (Diluted)(49.12)(53.60)(52.48)(5.36)(13.56)
Weighted Avg Shares15.91M16.48M17.64M75.52M89.03M
Weighted Avg Shares (Diluted)15.91M16.48M17.64M75.52M89.03M

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.